ES2571039T3 - Composiciones celulares para uso en terapia - Google Patents

Composiciones celulares para uso en terapia

Info

Publication number
ES2571039T3
ES2571039T3 ES09771581T ES09771581T ES2571039T3 ES 2571039 T3 ES2571039 T3 ES 2571039T3 ES 09771581 T ES09771581 T ES 09771581T ES 09771581 T ES09771581 T ES 09771581T ES 2571039 T3 ES2571039 T3 ES 2571039T3
Authority
ES
Spain
Prior art keywords
composition
therapy
cellular compositions
h2po4
trolox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09771581T
Other languages
English (en)
Inventor
Andrew Hope
Erik Miljan
John Sinden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reneuron Ltd
Original Assignee
Reneuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneuron Ltd filed Critical Reneuron Ltd
Application granted granted Critical
Publication of ES2571039T3 publication Critical patent/ES2571039T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Una composición para uso en terapia que comprende: i) Trolox, Na+, K+, Ca2+, Mg2+, Cl-, H2PO4 -, HEPES, lactobionato, sacarosa, manitol, glucosa, dextrano, adenosina y glutatión; y ii) células madre neurales humanas o mesenquimales, en la que la composición no incluye un disolvente aprótico dipolar, en particular DMSO, y en la que la composición es adecuada para el almacenamiento a temperaturas criogénicas y, después de descongelar, es adecuada para la administración directa a un paciente sin requerir adicionales procesamientos.
ES09771581T 2008-12-05 2009-12-07 Composiciones celulares para uso en terapia Active ES2571039T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0822246.5A GB0822246D0 (en) 2008-12-05 2008-12-05 Composition
PCT/GB2009/051659 WO2010064054A1 (en) 2008-12-05 2009-12-07 Cellular compositions for use in therapy

Publications (1)

Publication Number Publication Date
ES2571039T3 true ES2571039T3 (es) 2016-05-23

Family

ID=40289565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09771581T Active ES2571039T3 (es) 2008-12-05 2009-12-07 Composiciones celulares para uso en terapia

Country Status (8)

Country Link
US (1) US9265795B2 (es)
EP (1) EP2367419B1 (es)
JP (2) JP5698674B2 (es)
AU (1) AU2009323841B2 (es)
CA (1) CA2745539C (es)
ES (1) ES2571039T3 (es)
GB (1) GB0822246D0 (es)
WO (1) WO2010064054A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0822246D0 (en) * 2008-12-05 2009-01-14 Reneuron Ltd Composition
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method
WO2013143822A1 (en) 2012-03-26 2013-10-03 Imax Discovery Gmbh Adenosine as sweetness enhancer for certain sugars
GB201317887D0 (en) 2013-10-09 2013-11-20 Reneuron Ltd Product
CA2948820C (en) 2014-05-12 2022-03-22 Jonathan Allen Rowley Ready-to-print cells and integrated devices
FR3035407B1 (fr) 2015-04-23 2022-06-17 Francais Du Sang Ets Procede de conservation de cellules, tissus ou organes en hypothermie
WO2017019590A1 (en) * 2015-07-24 2017-02-02 Roosterbio, Inc. Biopreserved stem cells on microcarriers
EP3380078B1 (en) * 2015-11-23 2021-01-13 Association for the Advancement of Tissue Engineering and Cell based Technologies & Therapies (A4TEC) - Associação Composition comprising polyeletrolyte complexes, methods and uses thereof
US11297828B2 (en) 2016-03-14 2022-04-12 The Regents Of The University Of Michigan Surface tension mediated lyo-processing technique for preservation of biologics
RU2659842C2 (ru) * 2016-12-27 2018-07-04 федеральное государственное бюджетное образовательное учреждение "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Носитель для трансплантируемых клеток для замещения дефекта, полученного при черепно-мозговой травме
US11400119B2 (en) 2018-04-09 2022-08-02 Cellresearch Corporation Pte. Ltd. Method of transporting mesenchymal stem cells by means of a transporting solution and a method of administering stem cells to wounds
WO2020058324A1 (en) * 2018-09-20 2020-03-26 Citospin, S.L. Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
KR20210102195A (ko) 2018-10-12 2021-08-19 레뉴런 리미티드 조건부 불멸화를 위한 제어가능한 트랜스진을 포함하는 유도된 만능 세포
WO2020165404A1 (en) 2019-02-15 2020-08-20 Rigshospitalet Stem cell therapy for lacrimal gland dysfunction
EP3923959A1 (en) 2019-02-15 2021-12-22 Rigshospitalet Stem cell therapy for patients with salivary gland dysfunction
CN110724668B (zh) * 2019-11-20 2023-12-05 上海市第五人民医院 一种用于构建体外肿瘤模型的3d支架及其制备方法和应用
GB202005494D0 (en) 2020-04-15 2020-05-27 Reneuron Ltd Induced pluripotent cell comprising a contollable transgene for conditional immortalisation
EP3909593A1 (en) 2020-05-15 2021-11-17 Rigshospitalet Stem cells for treating skin lesions
CN115251038A (zh) * 2021-04-30 2022-11-01 中国科学院化学研究所 包含丝素蛋白的冷冻保存液及其应用和控冰冻存方法
CN115349515A (zh) * 2022-08-02 2022-11-18 华院计算技术(上海)股份有限公司 细胞保存液、细胞保存方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518606D0 (en) 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
CA2311729A1 (en) 1998-01-23 1999-07-29 Imclone Systems Incorporated Purified populations of stem cells
DE69929681T2 (de) * 1998-03-18 2006-10-26 Osiris Therapeutics, Inc. Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
AU6276899A (en) 1998-09-29 2000-04-17 Diacrin, Inc. Transplantation of neural cells for the treatment of ischemic damage due to stroke
GB9907243D0 (en) 1999-03-29 1999-05-26 Reneuron Ltd Therapy
US6399384B1 (en) 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
US6465215B1 (en) 1999-12-14 2002-10-15 Reneuron Limited Identification of cells for transplantation
US20070048726A1 (en) * 2000-01-14 2007-03-01 Biolife Solutions, Inc. Methods and Compositions for the Control of Molecular-Based Cell Death During Preservation of Cells, Tissues or Organs in a Gel-Like State
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
ATE473751T1 (de) * 2000-02-11 2010-07-15 Schepens Eye Res Inst Isolierung und transplantation von retinalen stammzellen
CA2473503C (en) 2002-01-14 2010-01-05 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
RU2346981C2 (ru) * 2002-07-19 2009-02-20 Веста Терапьютикс, Инк. Способ получения жизнеспособных клеток печени человека, в том числе печеночных стволовых клеток/клеток-предшественников
US6921633B2 (en) 2002-11-18 2005-07-26 Biolife Solutions Incorporated Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
US7470538B2 (en) 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
GB0316685D0 (en) 2003-07-17 2003-08-20 Nissan Technical Ct Europ Ltd Detection system
US20070042339A1 (en) 2003-08-08 2007-02-22 Massachusetts General Hospital Preservation of biomaterials with transported preservation agents
ES2294650T3 (es) 2004-09-30 2008-04-01 Reneuron Limited Linea celular.
KR101429284B1 (ko) 2004-11-17 2014-08-11 뉴럴스템, 인크. 신경퇴행성 증상의 치료를 위한 인간 신경 세포의 이식
CA2609507C (en) * 2005-05-26 2014-10-21 Intercytex Limited Tissue repair using allogenic dermal fibroblasts
EP1888741B1 (en) 2005-05-27 2013-04-17 Viacell, Inc. Treatment of ischemia using stem cells
KR20080036590A (ko) 2005-07-28 2008-04-28 주식회사 브레인가드 줄기세포 구조 지지체로서의 탄소나노튜브
EP1789435B1 (en) 2005-09-12 2010-02-24 Industry Foundation of Chonnam National University A method for production of mature natural killer cell
GB0703188D0 (en) * 2007-02-19 2007-03-28 Roger Land Building Large scale production of stem cells
WO2008152640A2 (en) * 2007-06-13 2008-12-18 Pluristem Ltd. Three dimensional biocompatible scaffolds for ex-vivo expansion and transplantation of stem cells
KR20100042654A (ko) 2007-08-08 2010-04-26 교와 핫꼬 기린 가부시키가이샤 단리된 세포 집단
AU2009228056B2 (en) * 2008-03-27 2015-03-12 Biolife Solutions, Inc. Materials and methods for hypothermic collection of whole blood
GB0822246D0 (en) * 2008-12-05 2009-01-14 Reneuron Ltd Composition
GB0902034D0 (en) 2009-02-06 2009-03-11 Reneuron Ltd Method

Also Published As

Publication number Publication date
WO2010064054A1 (en) 2010-06-10
CA2745539A1 (en) 2010-06-10
JP2015051986A (ja) 2015-03-19
EP2367419B1 (en) 2016-02-17
US20120076854A1 (en) 2012-03-29
AU2009323841B2 (en) 2013-04-11
AU2009323841A1 (en) 2011-06-30
JP2012510986A (ja) 2012-05-17
GB0822246D0 (en) 2009-01-14
CA2745539C (en) 2017-01-24
EP2367419A1 (en) 2011-09-28
US9265795B2 (en) 2016-02-23
WO2010064054A8 (en) 2011-06-30
JP5698674B2 (ja) 2015-04-08

Similar Documents

Publication Publication Date Title
ES2571039T3 (es) Composiciones celulares para uso en terapia
ES2572211T3 (es) Regeneración de músculo esquelético utilizando células madre mesenquimales
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CL2013001874A1 (es) Compuesto derivado de adenosina; metodo in vivo o ex vivo para incrementar el número de celulas madre y progenitoras; kit para expandir células madre hematopoyéticas; uso de dicho compuesto para expansión de células madre hematopoyética para tratar inmunodeficiencia heredada, enfermedad autoinmune y/o un trastorno hematopoyético (divisional de la solicitud 2010-2009).
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
UY31596A1 (es) Nuevos derivados de insulina con perfil tiempo/accion extremadamente retardado
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
GT201400043A (es) Imidazopiridazinas sustituidas con amino
CR10345A (es) Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
GT201300080A (es) Proceso de elaboracion para derivados de pirimidina
AR111351A2 (es) FORMA CRISTALINA I DEL 17-a-PROPIONATO DE CORTEXOLONA, COMPOSICIÓN FARMACÉUTICA QUE LA CONTIENE Y SU EMPLEO EN EL TRATAMIENTO DE UNA PATOLOGÍA RELACIONADA CON EL APARATO UROGENITAL, ENDÓCRINO O DE LA PIEL Y/O ANEXOS DE ÉSTA
BR112015006790A2 (pt) composição de cetoprofeno tópico
AR046690A1 (es) Composiciones de adn estabilizado para recubrir microproyecciones
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
AR102779A1 (es) Composición farmacéutica, su preparación y sus usos
ECSP066777A (es) Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de inflamacion
DOP2021000056A (es) Derivados de azitromicina y roxitromicina como fármacos senolíticos
HN2010000128A (es) Imidazoles sustituidos con heterociclilamida
DOP2011000356A (es) Una composicion para obtener un fungicida y bactericida biologico, sin el uso de antibioticos, para el control de enfermedades en plantas, compuesta por cepas nativas de los biocontroladores bacillus spp y brevibacillus parabrevis